A detailed history of Vanguard Group Inc transactions in Immunic, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,700,016 shares of IMUX stock, worth $4.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,700,016
Previous 3,740,047 25.67%
Holding current value
$4.7 Million
Previous $4.15 Million 86.82%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.08 - $1.95 $1.04 Million - $1.87 Million
959,969 Added 25.67%
4,700,016 $7.76 Million
Q2 2024

Aug 13, 2024

BUY
$0.98 - $1.44 $339,080 - $498,240
346,000 Added 10.19%
3,740,047 $4.15 Million
Q1 2024

May 10, 2024

BUY
$1.14 - $1.53 $1.94 Million - $2.61 Million
1,703,047 Added 100.71%
3,394,047 $4.48 Million
Q4 2023

Feb 14, 2024

BUY
$0.97 - $1.6 $27,558 - $45,457
28,411 Added 1.71%
1,691,000 $2.54 Million
Q3 2023

Nov 14, 2023

SELL
$1.35 - $2.87 $18,474 - $39,275
-13,685 Reduced 0.82%
1,662,589 $2.44 Million
Q2 2023

Aug 14, 2023

BUY
$1.33 - $2.51 $226,898 - $428,205
170,600 Added 11.33%
1,676,274 $4.21 Million
Q1 2023

May 15, 2023

BUY
$1.35 - $2.87 $586,242 - $1.25 Million
434,254 Added 40.53%
1,505,674 $2.24 Million
Q4 2022

Feb 10, 2023

BUY
$1.13 - $10.8 $86,726 - $828,889
76,749 Added 7.72%
1,071,420 $1.5 Million
Q3 2022

Nov 14, 2022

BUY
$3.0 - $5.49 $346,947 - $634,913
115,649 Added 13.16%
994,671 $3.14 Million
Q2 2022

Aug 12, 2022

SELL
$3.13 - $12.25 $243,122 - $951,518
-77,675 Reduced 8.12%
879,022 $3.05 Million
Q1 2022

May 13, 2022

BUY
$9.54 - $14.26 $523,431 - $782,403
54,867 Added 6.08%
956,697 $10.8 Million
Q4 2021

Feb 14, 2022

BUY
$7.34 - $10.25 $151,387 - $211,406
20,625 Added 2.34%
901,830 $8.63 Million
Q3 2021

Nov 12, 2021

BUY
$8.05 - $13.29 $1.36 Million - $2.25 Million
169,432 Added 23.8%
881,205 $7.8 Million
Q2 2021

Aug 13, 2021

BUY
$11.76 - $16.85 $8.37 Million - $12 Million
711,773 New
711,773 $8.73 Million

Others Institutions Holding IMUX

About IMMUNIC, INC.


  • Ticker IMUX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,565,000
  • Market Cap $30.6M
  • Description
  • Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...
More about IMUX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.